

where the [ ] symbols in the formula have the following meanings:

Ring A:

- (1) an aryl aromatic hydrocarbon group having 6 to 14 carbon atoms
- (2) a heteroaryl group having 1 to 4 hetero atoms selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom
- (3) a cycloalkyl group having 3 to 8 carbon atoms
- (4) a cycloalkenyl group having 3 to 8 carbon atoms
- (5) a 5- to 7-membered saturated heterocyclic group;

wherein groups (1) to (5) above may be unsubstituted or substituted by one or more substituents selected from the group consisting of a halogen atom, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxy carbonyl group, a lower acyl group, a mercapto group, a lower alkylthio group, a sulfonyl group, a lower alkylsulfonyl group, a sulfinyl group, a lower alkylsulfinyl group, a sulfonamido group, a lower alkanesulfonamido group, a carbamoyl group, a thiocarbamoyl group, a mono- or di-lower alkylcarbamoyl group, a nitro group, a cyano group, an amino group, a mono- or di-lower alkylamino group, a methylenedioxy group, an ethylenedioxy group and a lower alkyl group which may be substituted by a halogen atom, a hydroxyl group, a lower alkoxy group, an amino group or mono- or di-lower alkylamino group [an aryl group, a cycloalkyl group, a cycloalkenyl group, a heteroaryl group having 1 to 4 hetero atoms selected from the group consisting of an oxygen atom, a nitrogen atoms and a sulfur atom or a 5- to 7-membered saturated heterocyclic group, wherein said ring may be substituted by an optional substituent;]

AMENDMENT UNDER 37 C.F.R § 1.111  
U.S. Appln. No. 08/860,377

*C1  
Claim 8*

X: a single bond or a methylene group;

R: a halogen atom, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxycarbonyl group, a lower acyl group, a mercapto group, a lower alkylthio group, a sulfonyl group, a lower alkylsulfonyl group, a sulfinyl group, a lower alkylsulfinyl group, a sulfonamido group, a lower alkanesulfonamido group, a carbamoyl group, a thiocarbamoyl group, a mono- or di-lower alkylcarbamoyl group, a nitro group, a cyano group, an amino group, a mono- or di-lower alkylamino group, a ~~methylenedioxy~~ group, an ethylenedioxy group or a lower alkyl group which may be substituted by a halogen atom, a hydroxyl group, a lower alkoxy group, an amino group or a mono- or di-lower alkylamino group;

l: 0 or 1;


m: 0 or an integer of 1 to 3, and

n: an integer of 1 or 2[D],  
a salt thereof, an N-oxide thereof, or a quaternary ammonium salt thereof.

Kindly cancel without prejudice claim 2.

Claim 8, next to the last line, delete "and optically active substances thereof".

*1.9* (Amended) A pharmaceutical composition which comprises a quinuclidine derivative represented by the following formula (I):



AMENDMENT UNDER 37 C.F.R. § 1.111  
U.S. Appln. No. 08/860,377

where the [ ] symbols in the formula have the following meanings:

Ring A: (1) an aryl group having 6 to 14 carbon atoms  
(2) a heteroaryl group having 1 to 4 hetero atoms selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom  
(3) a cycloalkyl group having 3 to 8 carbon atoms  
(4) a cycloalkenyl group having 3 to 8 carbon atoms  
(5) a 5- to 7-membered saturated heterocyclic group;  
wherein groups (1) to (5) above may be unsubstituted or substituted by one or more substituents selected from the group consisting of a halogen atom, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxy carbonyl group, a lower acyl group, a mercapto group, a lower alkylthio group, a sulfonyl group, a lower alkylsulfonyl group, a sulfinyl group, a lower alkylsulfinyl group, a sulfonamido group, a lower alkanesulfonamido group, a carbamoyl group, a thiocarbamoyl group, a mono- or di-lower alkyl carbamoyl group, a nitro group, a cyano group, an amino group, a mono- or di-lower alkylamino group, a methylenedioxy group, an ethylenedioxy group and a lower alkyl group which may be substituted by a halogen atom, a hydroxyl group, a lower alkoxy group, an amino group or mono- or di-lower alkylamino group  
[an aryl group, a cycloalkyl group, a cycloalkenyl group, a heteroaryl group having 1 to 4 hetero atoms selected from the group consisting of an oxygen atom, a nitrogen atoms and a sulfur atom or a 5- to 7-membered saturated heterocyclic group, wherein said ring may be substituted by an optional substituent;]

X: a single bond or a methylene group;

R: a halogen atom, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxycarbonyl group, a lower acyl group, a mercapto group, a lower alkylthio group, a sulfonyl group, a lower alkylsulfonyl group, a sulfinyl group, a lower alkylsulfinyl group, a sulfonamido group, a lower alkanesulfonamido group, a carbamoyl group, a thiocarbamoyl group, a mono- or di-lower alkylcarbamoyl group, a nitro group, a cyano

AMENDMENT UNDER 37 C.F.R § 1.111  
U.S. Appln. No. 08/860,377

group, an amino group, a mono- or di-lower alkylamino group, a ~~methylenedioxy~~ group, an ethylenedioxy group or a lower alkyl group which may be substituted by a halogen atom, a hydroxyl group, a lower alkoxy group, an amino group or a mono- or di-lower alkylamino group;

l: 0 or 1;

m: 0 or an integer of 1 to 3, and

n: an integer of 1 or 2, or

a salt thereof, an N-oxide thereof, or a quaternary ammonium salt thereof, and a pharmaceutically acceptable carrier.

Please cancel without prejudice claims 12 and 13.

Kindly add following new claim 14.

--14. A method of treating muscarine M<sub>3</sub>-related diseases comprising administering a therapeutically effective amount of a quinuclidine derivative or a salt thereof, an N-oxide or a quaternary ammonium salt as claimed in claim 1 as a muscarinic M<sub>3</sub> receptor antagonist to a patient in need of the same. --

**REMARKS**

Claims 1, 3-9 and 14 are all the claims pending in the application. The amended claims and newly added claim 14 are supported by the disclosure. Hence, entry is respectfully requested.